NVS-PI3K-2

NVS-PI3K-2 is a small molecule inhibitor that selectively targets the alpha isoform of phosphatidylinositol 3-kinase (PI3Kα). Developed by Novartis, it serves as a pharmacological tool to study the PI3K/AKT signaling pathway, which is often upregulated in inflammatory conditions like Chronic Obstructive Pulmonary Disease (COPD) and various cancers. In research settings, NVS-PI3K-2 has demonstrated the ability to inhibit AKT phosphorylation and reduce the secretion of pro-inflammatory cytokines, such as TNF-α and IL-6, in alveolar macrophages. Crucially, studies indicate that its anti-inflammatory activity does not compromise essential innate immune functions, including the phagocytosis of bacteria or the clearance of apoptotic cells (efferocytosis), making the PI3Kα pathway a potential therapeutic target that preserves host defense mechanisms.